The study was expanded to include @ additional patients with genotype @ infection who were randomly assigned to daclatasvir plus sofosbuvir , with or without ribavirin , for @ weeks ( @ previously untreated patients ) or @ weeks ( @ patients who had previous virologic failure with telaprevir or boceprevir plus peginterferon alfa-ribavirin ) .